Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy |
| |
Authors: | Shan-Shan Qi Jia-Hui Sun Hao-Han Yu |
| |
Institution: | 1. Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, The People’s Republic of China;2. Cancer Pharmacology Crown Bioscience Inc, Taicang, The People’s Republic of China;3. Nanjing DeBioChem Inc, Nanjing, The People’s Republic of China |
| |
Abstract: | To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development. |
| |
Keywords: | Combination chemotherapy nano drug co-delivery system (NDCDS) multidrug resistance (MDR) targeting nanoparticles drug delivery materials |
|
|